VEGF and LPS synergistically silence inflammatory response to Plasmodium berghei infection and protect against cerebral malaria

Keyphrases

• Vascular Endothelial Growth Factor 100%
• Cerebral Malaria 100%
• Infected Mice 50%
• Hypoxia 25%
• Axitinib 25%
• Splenomegaly 25%
• Vessel Integrity 25%
• Nuclear Factor Erythroid 2-related Factor 2 (Nrf2) 25%
• Malaria Infection 25%
• Heme oxygenase-1 (HO-1) 25%
• Anti-inflammatory Gene 25%
• Experimental Cerebral Malaria 25%
• Endothelial Damage 25%
• Microbial Infection 25%
• Prolonged Survival 25%
• Parasite Load 25%
• Cerebral Pathology 25%
• Life-threatening Complications 25%
• Inflammatory Process 25%
• Vascular Endothelial Growth Factor Receptor Inhibitor 25%
• Mouse Model 25%
• Plasmodium Infection 25%
• Plasmodium Berghei ANKA 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Plasmodium Berghei Infection 100%
• Vasculotropin 100%
• Lipopolysaccharide 100%
• Cerebral Malaria 100%
• Plasmodium berghei 16%
• Anti-Inflammatory Drug 16%
• Splenomegaly 16%
• Transcription Factor Nrf2 16%
• Malaria 16%
• Hypoxia 16%
• Vasculotropin Receptor 16%
• Obstruction 16%
• Axitinib 16%
• Malaria Falciparum 16%

Immunology and Microbiology

• Vasculotropin 100%
• Gene Expression Profiling 20%
• Plasmodium falciparum 20%
• Transcription Factor Nrf2 20%
• Axitinib 20%
• Parasite Load 20%